UNASSIGNED: @entity1 who have undergone SOT mount a lower immune response after vaccination with TIV compared to healthy controls. @entity2033 or SD TIV in pediatric SOT was given to subjects 3-17  yr and at least six  months post-transplant. Subjects were randomized 2:1 to receive either the @entity2033 (60   g) or the SD (15   g) TIV. Local and systemic reactions were solicited after each vaccination, and immune responses were measured before and after each vaccination. Thirty-eight subjects were enrolled. Mean age was 11.25  yr; 68% male, 45% renal, 26% heart, 21% liver, 5% lung, and 5% intestinal. Twenty-three subjects were given @entity2033 and 15 SD TIV. The median time since transplant receipt was 2.2  yr. No severe AEs or rejection was attributed to vaccination. The @entity2033 group reported more @entity925 and local reactions, fatigue, and body ache when compared to the SD cohort, but these were considered mild and resolved within three  days. Subjects in the @entity2033 group demonstrated a higher percentage of four-fold titer rise to H3N2 compared to the SD group. @entity2033 influenza vaccine was well tolerated and may have increased immunogenicity. A phase 2 trial is needed to confirm.

Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant XXXX .

@entity1 :: ('9606', 'Species') :: ['Children'] @entity925 :: ('MESH:D063806', 'Disease') :: ['tenderness'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD']
@entity1 :: (9606,Species) :: ['patients']
